![conference banner](/images/conference-banner.jpeg)
Abstract
Late onset Alzheimer’s disease (LOAD) is a non-familial, progressive neurodegenerative disease and the most prominent form of dementia in the elderly. Accumulating evidence suggests that LOAD not only results from the combined effects of variation in a number of genes and environmental factors, but also from epigenetic abnormalities such as histone modifications or DNA methylation. In comparison to monogenic diseases, LOAD exhibits numerous anomalies that suggest an epigenetic component in disease etiology. Evidence against a monogenic course and for an epigenetic component include: 1) the dominance of sporadic cases over familial ones and the low estimated concordance rates for monozygotic twins; 2) gender specific susceptibility and course of disease; 3) parent–of–origin effects, and late age of onset; 4) brain chromatin abnormalities, non–Mendelian inheritance patterns, and atypical levels of folate and homocysteine; and 5) monoallelic expression patterns of susceptibility genes [1]. The epigenome is particularly susceptible to deregulation during early embryonic and neonatal periods and thus disturbances during these periods can have latent lasting effects. The Latent Early-life Associated Regulation (LEARn) model attempts to explain these consequences from a brain specific point of view. In the present review we present the evidence that support the role of epigenetics in the development of AD and explore the potential pathways and mechanisms that may be involved.
Keywords: Alzheimer’s disease, cognitive function, amyloid hypothesis, APP, LOAD.
Current Alzheimer Research
Title:Do Epigenetic Pathways Initiate Late Onset Alzheimer Disease (LOAD): Towards a New Paradigm
Volume: 9 Issue: 5
Author(s): Syed Waseem Bihaqi, Axel Schumacher, Bryan Maloney, Debomoy K. Lahiri and Nasser H. Zawia
Affiliation:
Keywords: Alzheimer’s disease, cognitive function, amyloid hypothesis, APP, LOAD.
Abstract: Late onset Alzheimer’s disease (LOAD) is a non-familial, progressive neurodegenerative disease and the most prominent form of dementia in the elderly. Accumulating evidence suggests that LOAD not only results from the combined effects of variation in a number of genes and environmental factors, but also from epigenetic abnormalities such as histone modifications or DNA methylation. In comparison to monogenic diseases, LOAD exhibits numerous anomalies that suggest an epigenetic component in disease etiology. Evidence against a monogenic course and for an epigenetic component include: 1) the dominance of sporadic cases over familial ones and the low estimated concordance rates for monozygotic twins; 2) gender specific susceptibility and course of disease; 3) parent–of–origin effects, and late age of onset; 4) brain chromatin abnormalities, non–Mendelian inheritance patterns, and atypical levels of folate and homocysteine; and 5) monoallelic expression patterns of susceptibility genes [1]. The epigenome is particularly susceptible to deregulation during early embryonic and neonatal periods and thus disturbances during these periods can have latent lasting effects. The Latent Early-life Associated Regulation (LEARn) model attempts to explain these consequences from a brain specific point of view. In the present review we present the evidence that support the role of epigenetics in the development of AD and explore the potential pathways and mechanisms that may be involved.
Export Options
About this article
Cite this article as:
Waseem Bihaqi Syed, Schumacher Axel, Maloney Bryan, K. Lahiri Debomoy and H. Zawia Nasser, Do Epigenetic Pathways Initiate Late Onset Alzheimer Disease (LOAD): Towards a New Paradigm, Current Alzheimer Research 2012; 9 (5) . https://dx.doi.org/10.2174/156720512800617982
DOI https://dx.doi.org/10.2174/156720512800617982 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot topic: Alzheimers Disease Drug Discovery: Aβ and Beyond (Guest Editors: D.W. Shineman and H.M. Fillit)]
Current Alzheimer Research The Outcome of Critical-phase COVID-19 in Liver Transplant Recipients
Current Respiratory Medicine Reviews Organic Antifungal Drugs and Targets of Their Action
Current Topics in Medicinal Chemistry A Review of Medicinal Plant Patents
Recent Patents on Biomedical Engineering (Discontinued) Administration of <i>Momordica charantia</i> Linnaeus Extracts for the Treatment of Hypothyroidism Induced Obesity in Mice and Study of Related Biochemical Parameters and Thyroid Histology
Current Functional Foods Role of Adiponectin in Obesity, Hypertension, and Metabolic Syndrome
Current Hypertension Reviews Inflammatory Responses to Respiratory Syncytial Virus (RSV) Infection and the Development of Immunomodulatory Pharmacotherapeutics
Current Medicinal Chemistry Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Current Treatment Strategies for Non-Alcoholic Fatty Liver Disease (NAFLD)
Current Drug Discovery Technologies The First Approved Agent in the Glitazar’s Class: Saroglitazar
Current Drug Targets Atherosclerotic Plaque Stabilization - Potential Role for Immunomodulatory Therapy
Vascular Disease Prevention (Discontinued) Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Type 2 Diabetes and Heart Failure: Challenges and Solutions
Current Cardiology Reviews The Long Run: Neuroprotective Effects of Physical Exercise on Adult Neurogenesis from Youth to Old Age
Current Neuropharmacology Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science Sleep Disorders Research From 1945 to 2020: A Bibliometric Analysis
CNS & Neurological Disorders - Drug Targets The Antioxidant Activity of Coumarins and Flavonoids
Mini-Reviews in Medicinal Chemistry Recent Updates on the Association Between Alzheimer’s Disease and Vascular Dementia
Medicinal Chemistry Comparison of 24-Hour Electrocardiogram Parameters in Patients with Graves’ Disease Before and After Anti-Thyroid Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies
Current Diabetes Reviews